Molecular glue degraders can induce or stabilize the interaction between E3 ubiquitin ligase and substrates, and accomplish the degradation of substrates through the ubiquitin-proteasome system. The rational design of molecular glue degraders, the selectivity of substrates and the targeted degradation of neosubstrates have always been difficult problems in academia and industry. Gluetacs Therapeutics has a systematic and modularized molecular glue degrader R&D platform, with its own unique development model in artificial intelligence-aided drug design, high-throughput screening and synthesis, substrate degradation evaluation, and neosubstrate degradation validation. Currently, Gluetacs is committed to discovering the mechanism of action and structure-activity relationship between E3 ubiquitin ligase and neosubstrates the field of molecular glue degraders, and rationally designing highly selective candidates for undruggable targets to meet unmet medical needs.

1. How We Expand Undruggable Proteins To Be Druggable Utilizing Molecular Glues?

2. How Do We Explore Next Generation Molecular Glues？

3. Advantages of Glue Medicinal Chemistry platform

•Our novel-designed scaffolds Drive substrate selectivity and Improve efficacy 

•Designed molecular glue library Makes it powerful for degrading neo-substrates

•Drug-like molecular glue library Accelerates successful PCC discovery

4. What Have We Done Successfully and How About Our Next Step in Molecular Glues